Bibliography
- Lombardino JG, Lowe-III JA. A guide to drug discovery: the role of the medicinal chemist in drug discovery — then and now. Nat Rev Drug Discov 2004;3:853-62
- Cohen FJ. Macro trends in pharmaceutical innovation. Nat Rev Drug Discov 2005;4:78-84
- Lima LM, Barreiro EJ. Bioisosterism: a useful strategy for molecular modification and drug design. Curr Med Chem 2005;12:23-49
- Barreiro EJ. Strategy of molecular simplification in rational drug design: the discovery of a new cardioactive agent. Quim Nova 2002;25:1172-80
- Viegas-Junior C, Danuello A, Bolzani VS, et al. Molecular hybridization: a useful tool in the design of new drug prototypes. Curr Med Chem 2007;14:18-29-1852
- Lazar C, Kluczyk A, Kiyota T, et al. Drug evolution concept in drug design: 1.Hybridization method. J Med Chem 2004;47:6973-82
- Terasaka T, Kinoshita T, Kuno M, et al. A highly potent non-nucleoside adenosine deaminase inhibitor. Efficient drug discovery by intentional lead hybridization. J Am Chem Soc 2004;126:34-5
- Jones LH, Allan G, Barba O, et al. Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays. J Med Chem 2009;52:1219-23
- Csemely P, Ágoston V, Pongor S. The efficiency of multi-target drugs: the network approach might help drug design. Trends Pharmacol Sci 2005;26:178-82
- Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008;4:682-90
- Wermuth CG. Multitargeted drugs: the end of the “one-target-one-disease” philosophy? Drug Discov Today 2004;9:826-7
- Morphy R, Kay C, Rankovic Z. From magic bullets to designed multiple ligands. Drug Discov Today 2004;9:641-51
- Barreiro EJ, Fraga CAM. New insights for multifactorial disease therapy: the challenge of the symbiotic drugs. Curr Drug Ther 2008;3:1-13
- Cardoso CR, Brito FCF, daSilva KCM, et al. Design, synthesis and pharmacological evaluation of novel pyrazolo[3,4-b]thieno[2,3-d]pyridine acid derivatives: a new class of anti-inflammatory and anti-platelet agents. Bioorg Med Chem Lett 2002;12:9-12
- Lima LM, Castro P, Machado AL, et al. Synthesis and anti-inflammatory activity of phthalimide derivatives, designed as new thalidomide analogues. Bioorg Med Chem 2002;10:3067-73
- Lacerda RB, Lima CKF, daSilva KCM, et al. Discovery of novel analgesic and anti-inflammatory 3-arylamine-imidazo[1,2-a]pyridine symbiotic prototypes. Bioorg Med Chem 2009;17:84-74
- daSilva GMS, Lima LM, Fraga CAM, et al. The molecular basis for coxib inhibition of p38α MAP kinase. Bioorg Med Chem Lett 2005;15:3506-9
- Espinoza-Fonseca LM. Knowledgebase for addiction-related genes: is it possible an extrapolation to rational multi-target drug design? Bioorg Med Chem 2008;16:9346-8
- Morphy R, Rankovic Z. Designed multiple ligands. An emerging drug discovery paradigm. J Med Chem 2005;48:6523-43
- Man-Chin C, Ferreira EI. The latentiation process in drug design. Quim Nova 1999;22:75-84